Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent/Refractory Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06948981
What this trial is testing

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Who this might be right for
Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)Ended earlyNCT01620216
What this trial is testing

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Lymphoblastic Leukemia+3 more
OHSU Knight Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT03770416
What this trial is testing

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Who this might be right for
Central Nervous System B-Cell Non-Hodgkin LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System Lymphoma
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07122609
What this trial is testing

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed and Refractory DLBCL
Ruijin Hospital 22
Early research (Phase 1)Study completedNCT00064090
What this trial is testing

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Vion Pharmaceuticals
Not applicableNot Yet RecruitingNCT07695896
What this trial is testing

Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Yanyan Liu 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07607925
What this trial is testing

Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Who this might be right for
Lymphoma, Non-Hodgkin
GlaxoSmithKline 49
Early research (Phase 1)UnknownNCT00769613
What this trial is testing

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Who this might be right for
Cancer
Milton S. Hershey Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT01445080
What this trial is testing

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Who this might be right for
Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT03096782
What this trial is testing

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Leukemia+19 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT00006350
What this trial is testing

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Not applicableNot Yet RecruitingNCT07669194
What this trial is testing

Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Early research (Phase 1)Looking for participantsNCT05010005
What this trial is testing

Ruxolitinib and Duvelisib in People With Lymphoma

Who this might be right for
T-cell LymphomasNK-Cell LymphomasT-cell Prolymphocytic Leukemia+1 more
Memorial Sloan Kettering Cancer Center 70
Not applicableLooking for participantsNCT07472972
What this trial is testing

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Who this might be right for
LymphomaLymphoid Hematological Malignancies
University of Zurich 50
Testing effectiveness (Phase 2)Looking for participantsNCT05533775
What this trial is testing

Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Mature B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche 65
Testing effectiveness (Phase 2)Ended earlyNCT03401853
What this trial is testing

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more
University of Washington 18
Early research (Phase 1)Active Not RecruitingNCT02992522
What this trial is testing

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Lymphoma, UnspecifiedGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+10 more
Beth Christian 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Next Page